Revolution Medicines insider plans $2.8M stock sale

Mark A. Goldsmith has filed a Rule 144 notice covering planned sales of RSU-related Revolution Medicines common stock alongside substantial recent sales.

Available on EDGAR 09/15/2026 - 06:07 PM EDT Accepted by SEC EDGAR 09/15/2026 - 06:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) is the issuer of common stock that Mark A. Goldsmith plans to sell under Rule 144. A notice covers the proposed sale of 13,603 shares tied to RSU vesting on September 15, 2026, with an indicated aggregate market value of about $2,771,883.31. The notice also lists prior Rule 144 sales in the past three months by Goldsmith and related revocable trusts.

Key Figures

Shares proposed for Rule 144 sale: 13,603 shares Aggregate market value of proposed shares: $2,771,883.31 Shares outstanding: 214,336,418 shares +3 more

6 metrics

Shares proposed for Rule 144 sale 13,603 shares Common stock tied to RSU vesting, planned sale on September 15, 2026

Aggregate market value of proposed shares $2,771,883.31 Value associated with 13,603 shares of common stock in the Rule 144 notice

Shares outstanding 214,336,418 shares Revolution Medicines common stock outstanding for Rule 144 calculations

Recent sale by Mark A. Goldsmith 80,000 shares for $16,735,887.50 Common stock sale on August 21, 2026

Additional recent sale by Mark A. Goldsmith 10,020 shares for $1,564,310.38 Common stock sale on June 16, 2026

Trust sales on August 21, 2026 3,000 shares for $627,626.10; 3,000 shares for $627,593.26 Sales by Jonathan Goldsmith Revocable Trust and Rebecca Goldsmith Revocable Trust

Key Terms

Rule 144, RSU vesting, services rendered

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU vesting financial

"Common Stock | 09/15/2026 | RSU vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

services rendered financial

"13603 | 09/15/2026 | Services rendered"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Revolution Medicines (RVMD)?

It discloses that Mark A. Goldsmith intends to sell 13,603 shares of Revolution Medicines common stock under Rule 144, related to RSU vesting on September 15, 2026, and lists several sizable sales made in the prior three months.

How many RVMD shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 13,603 shares of Revolution Medicines common stock, associated with RSU vesting on September 15, 2026, acquired from the issuer as services rendered.

What recent RVMD stock sales has Mark A. Goldsmith reported in this Form 144?

The notice lists sales including 80,000 shares of common stock on August 21, 2026 for $16,735,887.50 and 10,020 shares on June 16, 2026 for $1,564,310.38, plus additional sales of 3,000 shares each by two revocable trusts on August 21, 2026.

What is the aggregate market value indicated for the RVMD shares in this Form 144?

The notice shows an aggregate market value of approximately $2,771,883.31 tied to the 13,603 shares of Revolution Medicines common stock covered by the planned Rule 144 sale.

How many Revolution Medicines (RVMD) shares are outstanding according to this Form 144?

The notice reports that 214,336,418 shares of Revolution Medicines common stock were outstanding in connection with the Rule 144 calculation, providing a share-count context for the proposed sale.

Who is the broker involved in the planned Rule 144 sale for RVMD?

The planned sale of Revolution Medicines common stock is listed through ETRADE Financial Corporation, located in Alpharetta, Georgia, as the broker handling the Rule 144 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001246842
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 Saginaw Drive Redwood City CALIFORNIA 94063
Phone	650-481-6801
Name of Person for Whose Account the Securities are To Be Sold	Goldsmith Mark A
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	13603	2771883.31	214336418	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/15/2026	RSU vesting	Issuer			13603	09/15/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark A Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	08/21/2026	80000	16735887.50
Jonathan Goldsmith Revocable Trust c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	08/21/2026	3000	627626.10
Rebecca Goldsmith Revocable Trust c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	08/21/2026	3000	627593.26
Mark A Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2026	10020	1564310.38

144: Remarks and Signature

Remarks
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/31/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jack Anders, as Attorney-in-fact for Mark A. Goldsmith
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)